Diagnostics / pathology

HRR Testing Moves Upfront in Prostate Cancer
FDA has moved talazoparib plus enzalutamide into metastatic androgen pathway modulation-naive or sensitive prostate cancer with HRR mutations. Molecular profiling can no longer be treated as a later-line exercise when it now determines first-line metastatic treatment.

Europe Has Plans. Implementation Is Lagging

FDA Redraws the TMB-High Treatment Line

ESCAT v2 Makes Resistance Clinically Actionable

A Second Step for Alzheimer’s Blood Tests

A Genetic Clue to Spinal Leukodystrophy

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

Preparedness Finally Has Capital

Precision Oncology Has a Scale Problem

Alzheimer’s Blood Tests Are Changing Decisions, Not Just Diagnoses
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
